share_log

Why Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Shaky Earnings Are Just The Beginning Of Its Problems

Why Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Shaky Earnings Are Just The Beginning Of Its Problems

爲什麼益盛藥業(SZSE:002566)動盪的收益只是其問題的開始
Simply Wall St ·  2024/11/02 07:22

Jilin Jian Yisheng Pharmaceutical Co., Ltd.'s (SZSE:002566) recent weak earnings report didn't cause a big stock movement. However, we believe that investors should be aware of some underlying factors which may be of concern.

益盛藥業(SZSE:002566)最近的盈利報告較弱,並沒有造成大幅的股票波動。然而,我們認爲投資者應該關注一些可能令人擔憂的潛在因素。

big
SZSE:002566 Earnings and Revenue History November 1st 2024
SZSE:002566 盈利和營業收入歷史 2024年11月1日

How Do Unusual Items Influence Profit?

不尋常項目如何影響利潤?

Importantly, our data indicates that Jilin Jian Yisheng Pharmaceutical's profit received a boost of CN¥35m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Jilin Jian Yisheng Pharmaceutical had a rather significant contribution from unusual items relative to its profit to September 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

重要的是,我們的數據表明,益盛藥業在過去一年中因異常項目獲得了3500萬元的利潤提升。雖然我們很高興看到利潤增長,但當異常項目對利潤產生重大貢獻時,我們往往會更加謹慎。當我們分析全球絕大多數上市公司時,我們發現顯著的異常項目往往不會重複。而且,畢竟,這正是會計術語所暗示的。相比於截至2024年9月的利潤,益盛藥業的異常項目對利潤的貢獻相當顯著。因此,我們可以推測,異常項目使其法定利潤顯著高於本來的水平。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jilin Jian Yisheng Pharmaceutical.

注意:我們始終建議投資者檢查資產負債表的強度。點擊這裏查看我們對益盛藥業資產負債表的分析。

Our Take On Jilin Jian Yisheng Pharmaceutical's Profit Performance

我們對益盛藥業的利潤表現的看法

As previously mentioned, Jilin Jian Yisheng Pharmaceutical's large boost from unusual items won't be there indefinitely, so its statutory earnings are probably a poor guide to its underlying profitability. For this reason, we think that Jilin Jian Yisheng Pharmaceutical's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. In further bad news, its earnings per share decreased in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Jilin Jian Yisheng Pharmaceutical, you'd also look into what risks it is currently facing. Case in point: We've spotted 2 warning signs for Jilin Jian Yisheng Pharmaceutical you should be aware of.

正如之前提到的,益盛藥業因特殊項目而獲得的大幅提升不會無限期存在,因此其法定盈利可能無法很好地指引其潛在盈利能力。 基於這個原因,我們認爲,益盛藥業的法定利潤可能會誤導對其潛在盈利能力的判斷,從而可能給投資者帶來過於積極的公司印象。 更糟糕的是,其每股收益在去年有所下降。 當然,在分析其收益時我們才剛剛入門;還可以考慮利潤率、預測增長和投資回報等其他因素。 如果您想深入研究益盛藥業,您也應該關注它當前面臨的風險。 舉個例子:我們發現了您應該注意的益盛藥業的2個警告信號。

Today we've zoomed in on a single data point to better understand the nature of Jilin Jian Yisheng Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天我們聚焦於單一數據點,以更好地理解益盛藥業利潤的性質。 但如果您有能力關注細節,往往還有更多待發現的內容。 例如,許多人認爲高股本回報率是良好商業經濟的標誌,而其他人則喜歡「跟隨資金」,尋找內部人士正在買入的股票。 儘管這可能需要您花一些時間進行研究,但您可能會發現這份擁有高股本回報率公司的免費彙總,或是這份有顯著內部持股的股票列表會對您有幫助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論